Search

Rheumatoid Arthritis Drugs Market

Rheumatoid Arthritis Drugs Market Size by Type (Biopharmaceuticals, Pharmaceuticals), Mode of distribution (Over the Counter, Prescription), Mode of Administration (Oral, Subcutaneous, Intravenous) Regions, Global Industry Analysis, Share, Growth, Trends, and Forecast 2024 to 2033

Base Year: 2023 Historical Data: 2020-22
  • Report ID: TBI-12518
  • Published Date: Jul, 2024
  • Pages: 237
  • Category: Healthcare
  • Format: PDF
Buy @ $4700.00 Request Sample PDF

Market Dynamics

Drivers

  • Rising Geriatric Population

According to World health organization, the population aged 60 years and older is expected to total 2 billion by 2050, up from 900 million in 2015. Around 125 million people are aged 80 years or older in the present scenario. A shift in the distribution of country’s population towards older population (population ageing) started in developed and high income countries, it is now the developing countries that are going through the greatest change. The pace of population ageing across the globe is also rising vividly. The data also predicts about 80% of all older people will live in low and middle-income countries. Older age is also characterized by the emergence of several complex health states be likely to occur only later stages in life and these do not fall into distinct disease or their categories. Rheumatoid arthritis is most common in the old-age population. Thus, this primary factor is going to drive the market growth and development in the present scenario.

  • Increasing Incidences of Rheumatoid Arthritis

In the present scenario, there has been an upsurge in the rising incidences of rheumatoid arthritis. According to the research study conducted by Global Burden of Disease and Injuries, between 1 and 2 million of the population in North America suffer from of the rheumatoid arthritis. The study revealed the factors such as continuous cigarette smoking, vitamin D deficiency and lower dose synthetic estrogens in oral contraceptives are the main causes of rheumatoid arthritis to occur. This particular disease is often associated with increased morbidity rate, work-related disability, and shortened survival. Up to one-half of all rheumatoid arthritis patients become unable to work within 10 to 20 years of time period. This disease have a 60% to 70% higher mortality risk than those in the general population. Thus, higher instances of the rheumatoid arthritis in developed regions such as North America going to increase the demand of the pharmaceutical drugs in the market.

Restraints

  • High Cost Associated with the Manufacturing of Biosimilar Drugs

The interest of the biosimilar drugs continues to rise and pharmaceutical& drug manufacturers are making huge capital expenditure for new drug formulations in order to survive in a competitive environment. Biosimilar drugs are gaining a lot of attention due to the apparent cost-savings that consumers hope to gain coupled with opportunities for alternative pharmaceutical drug producers to enter both emerging and established markets. However, the whole manufacturing process of the biosimilar drugs and their products requires careful and strict manufacturing practices owing to the stringent rules and regulations formulated by U.S. Food and Drug Administration (FDA) regarding safety, requires a high cost and expenditure. Thus the price of the end-product also rises. Thus, this factor is going to restrain the market growth and development for the rheumatoid arthritis drugs market.

Opportunities

  • The Increasing Acceptance of Large Molecules Biologics by Rheumatologists

The increasing acceptance of the large molecule biologics by the rheumatologists is going to provide potential opportunities for the market to grow and flourish. Traditionally, autoimmune diseases such as rheumatic arthritis are tackled and managed by using biologics. Biologics are far more complex at the molecular level in comparison traditional chemically manufactured pharmaceuticals and drugs. They are much larger molecules than other drug classes of pharmaceuticals with an average molecular mass 100 times greater in comparison to aspirin. Their size and biologic properties preclude oral administration.

Challenges

  • Availability of Alternative Non-Drug Pain Management Therapies

The availability of non-drug pain management therapies and natural remedies for rheumatoid arthritis is going to hamper the market development and growth in the recent years. Natural remedies such as acupuncture, Tai-chi, and other exercises may is gaining popularity among the population. Studies have shown that acupuncture is rapidly becoming a mainstream treatment for pain. Acupuncture works for pain caused by many conditions, including fibromyalgia, arthritis, back injuries, sprain and sports related injuries. Tai-chi is an ancient martial art technique which helps dealing with rheumatoid arthritis. Tai-chi involves with slow and gentle movements along with deep breathing. Additionally, pain relieving gels, topical creams, and lotions if rubbed directly onto the skin helps in pain relieving.

Get Your Report Customized

  • Further segmentation of the market on the basis of type, application, end use, product, technology, method, process and any other segment depending on the market
  • Segmentation on the basis of any specific country or region
  • Any segment can be classified on the basis of application
  • Application segment can be further divided on the basis of companies
  • The companies profiled are not limited, we can incorporate additional companies of your choice
  • We can split the company market share on the basis of product, application and region
  • Report can be prepared for any specific country/region/segment
  • Customers can be added on the basis of regions and countries
Request for Customization

1. Introduction
    1.1. Objectives of the Study
    1.2. Market Definition
    1.3. Research Scope
    1.4. Currency
    1.5. Key Target Audience

2. Research Methodology and Assumptions

3. Executive Summary

4. Premium Insights
    4.1. Porter’s Five Forces Analysis
    4.2. Value Chain Analysis
    4.3. Top Investment Pockets
          4.3.1. Market Attractiveness Analysis By Type
          4.3.2. Market Attractiveness Analysis By Mode of Distribution
          4.3.3. Market Attractiveness Analysis By Mode of Administration
          4.3.4. Market Attractiveness Analysis By Region
    4.4. Industry Trends

5. Market Dynamics
    5.1. Market Evaluation
    5.2. Drivers
          5.2.1. Increasing Incidences of Rheumatoid Arthritis
          5.2.2. Rapid Growth in the Geriatric Population
    5.3. Restraints
          5.3.1. High cost associated with the manufacturing of Biosimilar Drugs
          5.3.2. Patent expiration of blockbuster drugs
    5.4. Opportunities
          5.4.1. The increasing acceptance of large molecules biologics by rheumatologists
    5.5. Challenges
          5.5.1. Availability of Alternative Non-Drug Pain Management Therapies

6. Global Rheumatoid Arthritis Drugs Market Analysis and Forecast, By Type
    6.1. Segment Overview
    6.2. Pharmaceuticals
          6.2.1. NSAIDs
          6.2.2. Analgesics
          6.2.3. DMARDs
          6.2.4. Glucocorticoids
    6.3. Biopharmaceuticals
          6.3.1. Biologics
                   6.3.1.1. T-cell inhibitors
                   6.3.1.2. CD20 antigen
                   6.3.1.3. JAK inhibitors
                   6.3.1.4. Anti-IL6 biologics
          6.3.2. Biosimilars
                   6.3.2.1. CD20 antigen
                   6.3.2.2. TNF-α antagonists
                   6.3.2.3. Others

7. Global Rheumatoid Arthritis Drugs Market Analysis and Forecast, By Mode of Distribution
    7.1. Segment Overview
    7.2. OTC
    7.3. Prescription

8. Global Rheumatoid Arthritis Drugs Market Analysis and Forecast, By Mode of Administration
    8.1. Segment Overview
    8.2. Oral
    8.3. Subcutaneous
    8.4. Intravenous

9. Global Rheumatoid Arthritis Drugs MarketAnalysis and Forecast, By Regional Analysis
    9.1. Segment Overview
    9.2. North America
          9.2.1. U.S.
          9.2.2. Canada
          9.2.3. Mexico
    9.3. Europe
          9.3.1. Germany
          9.3.2. France
          9.3.3. U.K.
          9.3.4. Italy
          9.3.5. Spain
    9.4. Asia-Pacific
          9.4.1. Japan
          9.4.2. China
          9.4.3. India
    9.5. South America
          9.5.1. Brazil
    9.6. Middle East and Africa
          9.6.1. UAE
          9.6.2. South Africa

10. Global Rheumatoid Arthritis Drugs Market-Competitive Landscape
    10.1. Overview
    10.2. Market Share of Key Players in the Rheumatoid Arthritis Drugs Market
          10.2.1. Global Company Market Share
          10.2.2. North America Company Market Share
          10.2.3. Europe Company Market Share
          10.2.4. APAC Company Market Share
    10.3. Competitive Situations and Trends
          10.3.1. Product Launches and Developments
          10.3.2. Partnerships, Collaborations, and Agreements
          10.3.3. Mergers & Acquisitions
          10.3.4. Expansions

11. Company Profiles
    11.1. Boehringer Ingelheim GmbH
          11.1.1. Business Overview
          11.1.2. Company Snapshot
          11.1.3. Company Market Share Analysis
          11.1.4. Company Product Portfolio
          11.1.5. Recent Developments
          11.1.6. SWOT Analysis
    11.2. Regeneron Pharmaceuticals, Inc.
          11.2.1. Business Overview
          11.2.2. Company Snapshot
          11.2.3. Company Market Share Analysis
          11.2.4. Company Product Portfolio
          11.2.5. Recent Developments
          11.2.6. SWOT Analysis
    11.3. Johnson & Johnson
          11.3.1. Business Overview
          11.3.2. Company Snapshot
          11.3.3. Company Market Share Analysis
          11.3.4. Company Product Portfolio
          11.3.5. Recent Developments
          11.3.6. SWOT Analysis
    11.4. Amgen Inc.
          11.4.1. Business Overview
          11.4.2. Company Snapshot
          11.4.3. Company Market Share Analysis
          11.4.4. Company Product Portfolio
          11.4.5. Recent Developments
          11.4.6. SWOT Analysis
    11.5. Eli Lilly
          11.5.1. Business Overview
          11.5.2. Company Snapshot
          11.5.3. Company Market Share Analysis
          11.5.4. Company Product Portfolio
          11.5.5. Recent Developments
          11.5.6. SWOT Analysis
    11.6. Bristol-Meyers Squibb Company
          11.6.1. Business Overview
          11.6.2. Company Snapshot
          11.6.3. Company Market Share Analysis
          11.6.4. Company Product Portfolio
          11.6.5. Recent Developments
          11.6.6. SWOT Analysis
    11.7. UCB S.A.
          11.7.1. Business Overview
          11.7.2. Company Snapshot
          11.7.3. Company Market Share Analysis
          11.7.4. Company Product Portfolio
          11.7.5. Recent Developments
          11.7.6. SWOT Analysis
    11.8. Pfizer, Inc.
          11.8.1. Business Overview
          11.8.2. Company Snapshot
          11.8.3. Company Market Share Analysis
          11.8.4. Company Product Portfolio
          11.8.5. Recent Developments
          11.8.6. SWOT Analysis
    11.9. AbbVie
          11.9.1. Business Overview
          11.9.2. Company Snapshot
          11.9.3. Company Market Share Analysis
          11.9.4. Company Product Portfolio
          11.9.5. Recent Developments
          11.9.6. SWOT Analysis
    11.10. F. Hoffmann-La Roche AG
          11.10.1. Business Overview
          11.10.2. Company Snapshot
          11.10.3. Company Market Share Analysis
          11.10.4. Company Product Portfolio
          11.10.5. Recent Developments
          11.10.6. SWOT Analysis
    11.11. Novartis International AG
          11.11.1. Business Overview
          11.11.2. Company Snapshot
          11.11.3. Company Market Share Analysis
          11.11.4. Company Product Portfolio
          11.11.5. Recent Developments
          11.11.6. SWOT Analysis

List of Table

1. Global Rheumatoid Arthritis Drugs Market, By Type, 2020–2033 (USD Billion)

2. Global Pharmaceuticals Rheumatoid Arthritis Drugs Market, By Region, 2020–2033 (USD Billion)

3. Global Biopharmaceuticals Rheumatoid Arthritis Drugs Market, By Region, 2020–2033 (USD Billion)

4. Global Rheumatoid Arthritis Drugs Market, By Mode of Distribution, 2020–2033 (USD Billion)

5. Global OTC, Rheumatoid Arthritis Drugs Market, By Region, 2020–2033 (USD Billion)

6. Global Prescription, Rheumatoid Arthritis Drugs Market, By Region, 2020–2033 (USD Billion)

7. Global Rheumatoid Arthritis Drugs Market, By Mode of Administration, 2020–2033 (USD Billion)

8. Global Oral, Rheumatoid Arthritis Drugs Market, By Region, 2020–2033 (USD Billion)

9. Global Intravenous, Rheumatoid Arthritis Drugs Market, By Region, 2020–2033 (USD Billion)

10. Global Subcutaneous, Rheumatoid Arthritis Drugs Market, By Region, 2020–2033 (USD Billion)

11. Global Rheumatoid Arthritis Drugs Market, By Region, 2020–2033 (USD Billion)

12. Global Rheumatoid Arthritis Drugs Market, By North America, 2020–2033 (USD Billion)

13. North America Rheumatoid Arthritis Drugs Market, By Type, 2020–2033 (USD Billion)

14. North America Rheumatoid Arthritis Drugs Market, By Mode of Distribution, 2020–2033 (USD Billion)

15. North America Rheumatoid Arthritis Drugs Market, By Mode of Administration, 2020–2033 (USD Billion)

16. U.S. Rheumatoid Arthritis Drugs Market, By Type, 2020–2033 (USD Billion)

17. U.S. Rheumatoid Arthritis Drugs Market, By Mode of Distribution, 2020–2033 (USD Billion)

18. U.S. Rheumatoid Arthritis Drugs Market, By Mode of Administration, 2020–2033 (USD Billion)

19. Canada Rheumatoid Arthritis Drugs Market, By Type, 2020–2033 (USD Billion)

20. Canada Rheumatoid Arthritis Drugs Market, By Mode of Distribution, 2020–2033 (USD Billion)

21. Canada Rheumatoid Arthritis Drugs Market, By Mode of Administration, 2020–2033 (USD Billion)

22. Mexico Rheumatoid Arthritis Drugs Market, By Type, 2020–2033 (USD Billion)

23. Mexico Rheumatoid Arthritis Drugs Market, By Mode of Distribution, 2020–2033 (USD Billion)

24. Mexico Rheumatoid Arthritis Drugs Market, By Mode of Administration, 2020–2033 (USD Billion)

25. Europe Rheumatoid Arthritis Drugs Market, By Type, 2020–2033 (USD Billion)

26. Europe Rheumatoid Arthritis Drugs Market, By Mode of Distribution, 2020–2033 (USD Billion)

27. Europe Rheumatoid Arthritis Drugs Market, By Mode of Administration, 2020–2033 (USD Billion)

28. Germany Rheumatoid Arthritis Drugs Market, By Type, 2020–2033 (USD Billion)

29. Germany Rheumatoid Arthritis Drugs Market, By Mode of Distribution, 2020–2033 (USD Billion)

30. Germany Rheumatoid Arthritis Drugs Market, By Mode of Administration, 2020–2033 (USD Billion)

31. France Rheumatoid Arthritis Drugs Market, By Type, 2020–2033 (USD Billion)

32. France Rheumatoid Arthritis Drugs Market, By Mode of Distribution, 2020–2033 (USD Billion)

33. France Rheumatoid Arthritis Drugs Market, By Mode of Administration, 2020–2033 (USD Billion)

34. U.K. Rheumatoid Arthritis Drugs Market, By Type, 2020–2033 (USD Billion)

35. U.K. Rheumatoid Arthritis Drugs Market, By Mode of Distribution, 2020–2033 (USD Billion)

36. U.K. Rheumatoid Arthritis Drugs Market, By Mode of Administration, 2020–2033 (USD Billion)

37. Italy Rheumatoid Arthritis Drugs Market, By Type, 2020–2033 (USD Billion)

38. Italy Rheumatoid Arthritis Drugs Market, By Mode of Distribution, 2020–2033 (USD Billion)

39. Italy Rheumatoid Arthritis Drugs Market, By Mode of Administration, 2020–2033 (USD Billion)

40. Spain Rheumatoid Arthritis Drugs Market, By Type, 2020–2033 (USD Billion)

41. Spain Rheumatoid Arthritis Drugs Market, By Mode of Distribution, 2020–2033 (USD Billion)

42. Spain Rheumatoid Arthritis Drugs Market, By Mode of Administration, 2020–2033 (USD Billion)

43. Asia Pacific Rheumatoid Arthritis Drugs Market, By Type, 2020–2033 (USD Billion)

44. Asia Pacific Rheumatoid Arthritis Drugs Market, By Mode of Distribution, 2020–2033 (USD Billion)

45. Asia Pacific Rheumatoid Arthritis Drugs Market, By Mode of Administration, 2020–2033 (USD Billion)

46. Japan Rheumatoid Arthritis Drugs Market, By Type, 2020–2033 (USD Billion)

47. Japan Rheumatoid Arthritis Drugs Market, By Mode of Distribution, 2020–2033 (USD Billion)

48. Japan Rheumatoid Arthritis Drugs Market, By Mode of Administration, 2020–2033 (USD Billion)

49. China Rheumatoid Arthritis Drugs Market, By Type, 2020–2033 (USD Billion)

50. China Rheumatoid Arthritis Drugs Market, By Mode of Distribution, 2020–2033 (USD Billion)

51. China Rheumatoid Arthritis Drugs Market, By Mode of Administration, 2020–2033 (USD Billion)

52. India Rheumatoid Arthritis Drugs Market, By Type, 2020–2033 (USD Billion)

53. India Rheumatoid Arthritis Drugs Market, By Mode of Distribution, 2020–2033 (USD Billion)

54. India Rheumatoid Arthritis Drugs Market, By Mode of Administration, 2020–2033 (USD Billion)

55. South America Rheumatoid Arthritis Drugs Market, By Type, 2020–2033 (USD Billion)

56. South America Rheumatoid Arthritis Drugs Market, By Mode of Distribution, 2020–2033 (USD Billion)

57. South America Rheumatoid Arthritis Drugs Market, By Mode of Administration, 2020–2033 (USD Billion)

58. Brazil Rheumatoid Arthritis Drugs Market, By Type, 2020–2033 (USD Billion)

59. Brazil Rheumatoid Arthritis Drugs Market, By Mode of Distribution, 2020–2033 (USD Billion)

60. Brazil Rheumatoid Arthritis Drugs Market, By Mode of Administration, 2020–2033 (USD Billion)

61. Middle East and Africa Rheumatoid Arthritis Drugs Market, By Type, 2020–2033 (USD Billion)

62. Middle East and Africa Rheumatoid Arthritis Drugs Market, By Mode of Distribution, 2020–2033 (USD Billion)

63. Middle East Rheumatoid Arthritis Drugs Market, By Mode of Administration, 2020–2033 (USD Billion)

64. UAE Rheumatoid Arthritis Drugs Market, By Type, 2020–2033 (USD Billion)

65. UAE Rheumatoid Arthritis Drugs Market, By Mode of Distribution, 2020–2033 (USD Billion)

66. UAE Rheumatoid Arthritis Drugs Market, By Mode of Administration, 2020–2033 (USD Billion)

67. South Africa Rheumatoid Arthritis Drugs Market, By Type, 2020–2033 (USD Billion)

68. South Africa Rheumatoid Arthritis Drugs Market, By Mode of Distribution, 2020–2033 (USD Billion)

69. South Africa Rheumatoid Arthritis Drugs Market, By Mode of Administration, 2020–2033 (USD Billion)

List of Figures 

1. Global Rheumatoid Arthritis Drugs Market Segmentation

2. Rheumatoid Arthritis Drugs Market: Research Methodology

3. Market Size Estimation Methodology: Bottom-Up Approach

4. Market Size Estimation Methodology: Top-Down Approach

5. Data Triangulation

6. Porter’s Five Forces Analysis 

7. Value Chain Analysis 

8. Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis By Type

9. Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis By Mode of Distribution

10. Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis By Mode of Administration

11. Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis By Region

12. Global Rheumatoid Arthritis Drugs Market: Dynamics

13. Global Rheumatoid Arthritis Drugs Market Share by Type (2023 & 2033)

14. Global Rheumatoid Arthritis Drugs Market Share by Mode of Distribution (2023 & 2033)

15. Global Rheumatoid Arthritis Drugs Market Share by Mode of Administration (2023 & 2033)

16. Global Rheumatoid Arthritis Drugs Market Share by Regions (2023 & 2033)

17. Global Rheumatoid Arthritis Drugs Market Share by Company (2023)

This study forecasts revenue at global, regional, and country levels from 2018 to 2030. The Brainy Insights has segmented the global Rheumatoid Arthritis Drugs market on the basis of below mentioned segments:

Global Rheumatoid Arthritis Drugs Market by Type:

  • Pharmaceuticals
    • NSAIDs
    • Analgesics
    • DMARDs
    • Glucocorticoids
  • Biopharmaceuticals
    • Biologics
      • T-cell inhibitors
      • CD20 antigen
      • JAK inhibitors
      • Anti-IL6 biologics
    • Biosimilars
      • CD20 antigen
      • TNF-α antagonists
      • Others

Global Rheumatoid Arthritis Drugs Market by Mode of Administration:

  • Oral
  • Subcutaneous
  • Intravenous

Global Rheumatoid Arthritis Drugs Market by Mode of Distribution:

  • OTC
  • Prescription

Global Rheumatoid Arthritis Drugs Market by Region:

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
  • Asia-Pacific
    • Japan
    • China
    • India
  • South America
    • Brazil
  • Middle East and Africa  
    • UAE
    • South Africa

Methodology

Research has its special purpose to undertake marketing efficiently. In this competitive scenario, businesses need information across all industry verticals; the information about customer wants, market demand, competition, industry trends, distribution channels etc. This information needs to be updated regularly because businesses operate in a dynamic environment. Our organization, The Brainy Insights incorporates scientific and systematic research procedures in order to get proper market insights and industry analysis for overall business success. The analysis consists of studying the market from a miniscule level wherein we implement statistical tools which helps us in examining the data with accuracy and precision. 

Our research reports feature both; quantitative and qualitative aspects for any market. Qualitative information for any market research process are fundamental because they reveal the customer needs and wants, usage and consumption for any product/service related to a specific industry. This in turn aids the marketers/investors in knowing certain perceptions of the customers. Qualitative research can enlighten about the different product concepts and designs along with unique service offering that in turn, helps define marketing problems and generate opportunities. On the other hand, quantitative research engages with the data collection process through interviews, e-mail interactions, surveys and pilot studies. Quantitative aspects for the market research are useful to validate the hypotheses generated during qualitative research method, explore empirical patterns in the data with the help of statistical tools, and finally make the market estimations.

The Brainy Insights offers comprehensive research and analysis, based on a wide assortment of factual insights gained through interviews with CXOs and global experts and secondary data from reliable sources. Our analysts and industry specialist assume vital roles in building up statistical tools and analysis models, which are used to analyse the data and arrive at accurate insights with exceedingly informative research discoveries. The data provided by our organization have proven precious to a diverse range of companies, facilitating them to address issues such as determining which products/services are the most appealing, whether or not customers use the product in the manner anticipated, the purchasing intentions of the market and many others.

Our research methodology encompasses an idyllic combination of primary and secondary initiatives. Key phases involved in this process are listed below:

MARKET RESEARCH PROCESS

Data Procurement:

The phase involves the gathering and collecting of market data and its related information with the help of different sources & research procedures.

The data procurement stage involves in data gathering and collecting through various data sources.

This stage involves in extensive research. These data sources includes:

Purchased Database: Purchased databases play a crucial role in estimating the market sizes irrespective of the domain. Our purchased database includes:

  • The organizational databases such as D&B Hoovers, and Bloomberg that helps us to identify the competitive scenario of the key market players/organizations along with the financial information.
  • Industry/Market databases such as Statista, and Factiva provides market/industry insights and deduce certain formulations. 
  • We also have contractual agreements with various reputed data providers and third party vendors who provide information which are not limited to:
    • Import & Export Data
    • Business Trade Information
    • Usage rates of a particular product/service on certain demographics mainly focusing on the unmet prerequisites

Primary Research: The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. Primary research mainly involves in telephonic interviews, E-mail interactions and face-to-face interviews with the raw material providers, manufacturers/producers, distributors, & independent consultants. The interviews that we conduct provides valuable data on market size and industry growth trends prevailing in the market. Our organization also conducts surveys with the various industry experts in order to gain overall insights of the industry/market. For instance, in healthcare industry we conduct surveys with the pharmacists, doctors, surgeons and nurses in order to gain insights and key information of a medical product/device/equipment which the customers are going to usage. Surveys are conducted in the form of questionnaire designed by our own analyst team. Surveys plays an important role in primary research because surveys helps us to identify the key target audiences of the market. Additionally, surveys helps to identify the key target audience engaged with the market. Our survey team conducts the survey by targeting the key audience, thus gaining insights from them. Based on the perspectives of the customers, this information is utilized to formulate market strategies. Moreover, market surveys helps us to understand the current competitive situation of the industry. To be precise, our survey process typically involve with the 360 analysis of the market. This analytical process begins by identifying the prospective customers for a product or service related to the market/industry to obtain data on how a product/service could fit into customers’ lives.

Secondary Research: The secondary data sources includes information published by the on-profit organizations such as World bank, WHO, company fillings, investor presentations, annual reports, national government documents, statistical databases, blogs, articles, white papers and others. From the annual report, we analyse a company’s revenue to understand the key segment and market share of that organization in a particular region. We analyse the company websites and adopt the product mapping technique which is important for deriving the segment revenue. In the product mapping method, we select and categorize the products offered by the companies catering to domain specific market, deduce the product revenue for each of the companies so as to get overall estimation of the market size. We also source data and analyses trends based on information received from supply side and demand side intermediaries in the value chain. The supply side denotes the data gathered from supplier, distributor, wholesaler and the demand side illustrates the data gathered from the end customers for respective market domain.

The supply side for a domain specific market is analysed by:

  • Estimating and projecting penetration rates through analysing product attributes, availability of internal and external substitutes, followed by pricing analysis of the product.
  • Experiential assessment of year-on-year sales of the product by conducting interviews.

The demand side for the market is estimated through:

  • Evaluating the penetration level and usage rates of the product.
  • Referring to the historical data to determine the growth rate and evaluate the industry trends

In-house Library: Apart from these third-party sources, we have our in-house library of qualitative and quantitative information. Our in-house database includes market data for various industry and domains. These data are updated on regular basis as per the changing market scenario. Our library includes, historic databases, internal audit reports and archives.

Sometimes there are instances where there is no metadata or raw data available for any domain specific market. For those cases, we use our expertise to forecast and estimate the market size in order to generate comprehensive data sets. Our analyst team adopt a robust research technique in order to produce the estimates:

  • Applying demographic along with psychographic segmentation for market evaluation
  • Determining the Micro and Macro-economic indicators for each region 
  • Examining the industry indicators prevailing in the market. 

Data Synthesis: This stage involves the analysis & mapping of all the information obtained from the previous step. It also involves in scrutinizing the data for any discrepancy observed while data gathering related to the market. The data is collected with consideration to the heterogeneity of sources. Robust scientific techniques are in place for synthesizing disparate data sets and provide the essential contextual information that can orient market strategies. The Brainy Insights has extensive experience in data synthesis where the data passes through various stages:

  • Data Screening: Data screening is the process of scrutinising data/information collected from primary research for errors and amending those collected data before data integration method. The screening involves in examining raw data, identifying errors and dealing with missing data. The purpose of the data screening is to ensure data is correctly entered or not. The Brainy Insights employs objective and systematic data screening grades involving repeated cycles of quality checks, screening and suspect analysis.
  • Data Integration: Integrating multiple data streams is necessary to produce research studies that provide in-depth picture to the clients. These data streams come from multiple research studies and our in house database. After screening of the data, our analysts conduct creative integration of data sets, optimizing connections between integrated surveys and syndicated data sources. There are mainly 2 research approaches that we follow in order to integrate our data; top down approach and bottom up approach.

Market Deduction & Formulation: The final stage comprises of assigning data points at appropriate market spaces so as to deduce feasible conclusions. Analyst perspective & subject matter expert based holistic form of market sizing coupled with industry analysis also plays a crucial role in this stage.

This stage involves in finalization of the market size and numbers that we have collected from data integration step. With data interpolation, it is made sure that there is no gap in the market data. Successful trend analysis is done by our analysts using extrapolation techniques, which provide the best possible forecasts for the market.

Data Validation & Market Feedback: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helps us finalize data-points to be used for final calculations.

The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. The data validation interview and discussion panels are typically composed of the most experienced industry members. The participants include, however, are not limited to:

  • CXOs and VPs of leading companies’ specific to sector
  • Purchasing managers, technical personnel, end-users
  • Key opinion leaders such as investment bankers, and industry consultants

Moreover, we always validate our data and findings through primary respondents from all the major regions we are working on.

Ask for customization Request Sample Speak to analyst Inquire before buying

Flexible Purchase Options

  • Chapters of your choice
  • Quantitative Information for Historical & Forecasted Data
  • Regional/Country Level Reports
Request for Special Pricing

Get in touch with us

+1-315-215-1633

sales@thebrainyinsights.com

Why choose us

ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems

Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach6 Major regions and 40+ countries level analysis accomplished

Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery

Some Facts About The Brainy Insights

50%

Free Customization

300+

Fortune 500 Clients

1

Free Yearly Update On Purchase Of Multi/Corporate License

900+

Companies Served Till Date